The stock price of Adma Biologics Inc (NASDAQ: ADMA) has plunged by -4.36 when compared to previous closing price of 20.40, but the company has seen a -6.47% decline in its stock price over the last five trading sessions. zacks.com reported 2025-06-16 that ADMA surges on soaring Asceniv demand and eyes pediatric label expansion to widen its immunodeficiency treatment reach.
Is It Worth Investing in Adma Biologics Inc (NASDAQ: ADMA) Right Now?
Adma Biologics Inc (NASDAQ: ADMA) has a higher price-to-earnings ratio of 23.11x compared to its average ratio. ADMA has 36-month beta value of 0.47. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ADMA is 230.42M, and currently, short sellers hold a 6.21% ratio of that float. The average trading volume of ADMA on June 17, 2025 was 3.49M shares.
ADMA’s Market Performance
ADMA’s stock has seen a -6.47% decrease for the week, with a -0.91% drop in the past month and a 4.28% gain in the past quarter. The volatility ratio for the week is 3.67%, and the volatility levels for the past 30 days are at 2.19% for Adma Biologics Inc The simple moving average for the last 20 days is -4.33% for ADMA stock, with a simple moving average of 3.63% for the last 200 days.
Analysts’ Opinion of ADMA
Many brokerage firms have already submitted their reports for ADMA stocks, with Raymond James repeating the rating for ADMA by listing it as a “Strong Buy.” The predicted price for ADMA in the upcoming period, according to Raymond James is $5 based on the research report published on July 19, 2023 of the previous year 2023.
Mizuho, on the other hand, stated in their research note that they expect to see ADMA reach a price target of $5. The rating they have provided for ADMA stocks is “Buy” according to the report published on October 13th, 2022.
Raymond James gave a rating of “Strong Buy” to ADMA, setting the target price at $5 in the report published on November 11th of the previous year.
ADMA Trading at -6.55% from the 50-Day Moving Average
After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.00% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADMA starting from ELMS STEVE, who sale 194,749 shares at the price of $20.24 back on Jun 16 ’25. After this action, ELMS STEVE now owns 87,330 shares of Adma Biologics Inc, valued at $3,941,720 using the latest closing price.
ELMS STEVE, the Director of Adma Biologics Inc, sale 137,931 shares at $20.82 during a trade that took place back on Jun 13 ’25, which means that ELMS STEVE is holding 282,079 shares at $2,871,723 based on the most recent closing price.
Stock Fundamentals for ADMA
Current profitability levels for the company are sitting at:
- 0.33 for the present operating margin
- 0.53 for the gross margin
The net margin for Adma Biologics Inc stands at 0.45. The total capital return value is set at 0.33. Equity return is now at value 78.45, with 48.01 for asset returns.
Based on Adma Biologics Inc (ADMA), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at 1.23. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is 18.57.
Currently, EBITDA for the company is 147.69 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 10.1. The receivables turnover for the company is 4.62for trailing twelve months and the total asset turnover is 0.9. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.58.
Conclusion
To put it simply, Adma Biologics Inc (ADMA) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
